Kitano, Shigehisa

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., et al. (2020) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 256

Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC

Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 195

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science

Thyroid Disorders and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 158

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Park, W., Kasi, A., Spira, A. I., Berlin, J. D., Wang, J. S., Herzberg, B., Kuboki, Y., Kitano, S., Pelster, M., Goldman, J. W., et al. (2024) · Annals of Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 46

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer

Yanai, Y., Kosaka, T., Mikami, S., Hongo, H., Yasumizu, Y., Takeda, T., Matsumoto, K., Miyauchi, J., Kitano, S., & Oya, M. (2021) · Scientific Reports

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 28